View Future GrowthHerbal Dispatch 過去の業績過去 基準チェック /06Herbal Dispatchは15.3%の年平均成長率で業績を伸ばしているが、Pharmaceuticals業界はgrowingで8.8%毎年増加している。売上は成長しており、年平均63.4%の割合である。主要情報15.27%収益成長率35.24%EPS成長率Pharmaceuticals 業界の成長7.33%収益成長率63.39%株主資本利益率-60.66%ネット・マージン-15.19%前回の決算情報31 Dec 2025最近の業績更新Reported Earnings • Aug 23Second quarter 2024 earnings released: EPS: CA$0.001 (vs CA$0.006 loss in 2Q 2023)Second quarter 2024 results: EPS: CA$0.001 (up from CA$0.006 loss in 2Q 2023). Revenue: CA$3.65m (up 215% from 2Q 2023). Net income: CA$58.6k (up CA$460.2k from 2Q 2023). Profit margin: 1.6% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue.Reported Earnings • May 02Full year 2023 earnings released: CA$0.029 loss per share (vs CA$0.092 loss in FY 2022)Full year 2023 results: CA$0.029 loss per share (improved from CA$0.092 loss in FY 2022). Revenue: CA$4.74m (up CA$4.43m from FY 2022). Net loss: CA$2.07m (loss narrowed 55% from FY 2022).Reported Earnings • Nov 25Third quarter 2023 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 3Q 2022)Third quarter 2023 results: CA$0.001 loss per share (in line with 3Q 2022). Revenue: CA$1.17m (up CA$1.07m from 3Q 2022). Net loss: CA$533.0k (loss narrowed 32% from 3Q 2022).Reported Earnings • Aug 31Second quarter 2023 earnings released: CA$0.001 loss per share (vs CA$0.003 loss in 2Q 2022)Second quarter 2023 results: CA$0.001 loss per share (improved from CA$0.003 loss in 2Q 2022). Revenue: CA$1.16m (up CA$1.15m from 2Q 2022). Net loss: CA$401.7k (loss narrowed 71% from 2Q 2022).Reported Earnings • Jun 02First quarter 2023 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 1Q 2022)First quarter 2023 results: CA$0.001 loss per share (in line with 1Q 2022). Net loss: CA$685.8k (loss widened 23% from 1Q 2022).Reported Earnings • May 01Full year 2022 earnings released: CA$0.009 loss per share (vs CA$0.006 loss in FY 2021)Full year 2022 results: CA$0.009 loss per share (further deteriorated from CA$0.006 loss in FY 2021). Net loss: CA$4.62m (loss widened 93% from FY 2021).すべての更新を表示Recent updatesBoard Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Drew Malcolm was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Oct 21Herbal Dispatch Inc. announced that it has received CAD 2.078211 million in fundingOn October 20, 2025, Herbal Dispatch Inc. closed the transaction. The company issued 41,564,220 units at a price of CAD 0.05 per Unit for gross proceeds of up to CAD 2,078,211. In connection with the closing of the private placement, the company incurred finder's fees to qualified arm’s length finders (the “finders”) as follows: (a) an aggregate cash payment of CAD 103,495; and (b) the issuance of 599,900 Warrants. Such finder’s fees were paid only to Finders who executed finder’s fee agreements with the Company and who successfully introduced investors that participated in the Private Placement. The transaction included participation from new investors Roderick W. Law Corporation, EPC Holdings Ltd., and ADH Holdings Ltd., for an aggregate of 6,814,420 Units, representing approximately 16.39% of the total Units permitted to be subscribed for under the Private Placement.お知らせ • Jul 30Herbal Dispatch Inc. announced that it expects to receive CAD 1 million in fundingHerbal Dispatch Inc. announced a non-brokered private placement of up to 20,000,000 units at a price of CAD 0.05 per Unit for gross proceeds of up to CAD 1,000,000. Each Unit shall consist of one common share and one-half common share purchase warrant with each Warrant transferable and exercisable for one common share at a price of CAD 0.08 per share for a period of 24 months after the closing date. The Private Placement shall be completed on a best-efforts basis from eligible purchasers that shall be restricted to accredited investors or other investors meeting exemption requirements for a non-brokered private placement. The closing of the Private Placement is expected to occur before August 29, 2025, and is subject to receipt of all necessary regulatory approvals, including the approval of the CSE. Should the Private Placement be oversubscribed, the Company reserves the right to accept additional funds, subject to the approval of the Canadian Securities Exchange (“CSE”). All securities issued pursuant to the Private Placement will be subject to a four month hold period in accordance with applicable Canadian securities laws.お知らせ • Apr 08Herbal Dispatch Inc., Annual General Meeting, Jun 10, 2025Herbal Dispatch Inc., Annual General Meeting, Jun 10, 2025.お知らせ • Mar 25Herbal Dispatch Inc. announced that it has received CAD 0.6 million in fundingHerbal Dispatch Inc. announced that it will receive CAD 600,000 in a round of funding on March 25, 2025. The company will also issue 3,000,000 warrants in the transaction. Each warrants are convertible to common stock of the company at an exercise price of $0.065 per share. The warrants will expire on March 19, 2029. The company has received debt in the transaction which incurs interest rate of 18% p.a. and is repayable in equal monthly instalments of $29,955. The warrants carry a hold period of four months. The company has incurred a closing fee of $12,000 in the transaction. The transaction included participation from Philip Campbell representing one of the Lenders, and via a wholly owned company, and provided $100,000 of the debt and will receive 500,100 of the warrants issued.お知らせ • Oct 09Herbal Dispatch Inc., Annual General Meeting, Dec 16, 2024Herbal Dispatch Inc., Annual General Meeting, Dec 16, 2024.Reported Earnings • Aug 23Second quarter 2024 earnings released: EPS: CA$0.001 (vs CA$0.006 loss in 2Q 2023)Second quarter 2024 results: EPS: CA$0.001 (up from CA$0.006 loss in 2Q 2023). Revenue: CA$3.65m (up 215% from 2Q 2023). Net income: CA$58.6k (up CA$460.2k from 2Q 2023). Profit margin: 1.6% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue.New Risk • May 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$472k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$472k free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Market cap is less than US$10m (€2.76m market cap, or US$2.98m). Minor Risks Shareholders have been diluted in the past year (11% increase in shares outstanding). Revenue is less than US$5m (CA$5.7m revenue, or US$4.2m).Board Change • May 13Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Drew Malcolm was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • May 10Herbal Dispatch Inc. Announces Board ChangesHerbal Dispatch Inc. announces that effective May 8, 2024, Jeremy South has resigned as a Director and Chairman of the Company. The Company is grateful to Mr. South for his contribution throughout the yearsand wishes him all the best in his future endeavors. The Honourable Herb Dhaliwal, a Director the Company, has agreed to be appointed as interim Chairman of the Company until a permanent successoris appointed.Reported Earnings • May 02Full year 2023 earnings released: CA$0.029 loss per share (vs CA$0.092 loss in FY 2022)Full year 2023 results: CA$0.029 loss per share (improved from CA$0.092 loss in FY 2022). Revenue: CA$4.74m (up CA$4.43m from FY 2022). Net loss: CA$2.07m (loss narrowed 55% from FY 2022).お知らせ • Mar 21Herbal Dispatch Inc. announced that it expects to receive CAD 1 million in fundingHerbal Dispatch Inc. announced on best-effort basis a non-brokered private placement of up to 20,000,000 units at a price of CAD 0.05 per unit for the gross proceeds of CAD 1,000,000 on March 20, 2024. Each Unit shall consist of one common share and one common share warrant with each Warrant exercisable for one common share at a price of CAD 0.06 per share for a period of 24 months after the closing date. Should the Private Placement be oversubscribed, the Company reserves the right to accept additional funds, subject to the approval of the Canadian Securities Exchange and is also subjected to regulatory approvals. The closing of the Private Placement is expected to occur before April 5, 2024. All securities issued pursuant to the private placement will be subject to a four month hold period in accordance with applicable Canadian securities laws.お知らせ • Dec 16Herbal Dispatch Inc. announced that it expects to receive CAD 0.938 million in fundingHerbal Dispatch Inc. announced that it has issued an unsecured convertible debenture in the principal amount of CAD 938,000 for gross proceeds of CAD 938,000 on December 15, 2023. The transaction included participation from directors. The company also amended the terms of a convertible debenture in the principal amount of CAD 438,000 owing to another director of the company. The debenture bears interest at an annual rate of 14% per annum, payable monthly, and matures on January 31, 2025. The transaction is subject to the approval of the Canadian Securities Exchange. The debenture will also be convertible, at the holder’s option into common shares of the company at a price of CAD 0.05 per share, and at the it’s election, during any period where the trading price of the it’s common shares is CAD 0.10 or greater for a period of 20 consecutive trading days. The company issued principal amount of CAD 500,000 to a director of the company in its first tranche.Reported Earnings • Nov 25Third quarter 2023 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 3Q 2022)Third quarter 2023 results: CA$0.001 loss per share (in line with 3Q 2022). Revenue: CA$1.17m (up CA$1.07m from 3Q 2022). Net loss: CA$533.0k (loss narrowed 32% from 3Q 2022).お知らせ • Oct 07Herbal Dispatch Inc., Annual General Meeting, Dec 15, 2023Herbal Dispatch Inc., Annual General Meeting, Dec 15, 2023.Reported Earnings • Aug 31Second quarter 2023 earnings released: CA$0.001 loss per share (vs CA$0.003 loss in 2Q 2022)Second quarter 2023 results: CA$0.001 loss per share (improved from CA$0.003 loss in 2Q 2022). Revenue: CA$1.16m (up CA$1.15m from 2Q 2022). Net loss: CA$401.7k (loss narrowed 71% from 2Q 2022).Reported Earnings • Jun 02First quarter 2023 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 1Q 2022)First quarter 2023 results: CA$0.001 loss per share (in line with 1Q 2022). Net loss: CA$685.8k (loss widened 23% from 1Q 2022).お知らせ • May 27Herbal Dispatch Inc. announced that it expects to receive CAD 1 million in fundingHerbal Dispatch Inc. announced a non-brokered private placement of up to 100,000,000 units at a price of CAD 0.01 per unit for the gross proceeds of CAD 1,000,000 on May 25, 2023. Each unit consist of one common share and one common share warrant. Each warrant is exercisable for one common share at a price of CAD 0.05 per share for a period of 24 months after the closing date. All securities issued pursuant to the private placement will be subject to a four month hold period. The transaction is subject to the approval of all necessary regulatory approvals including the approval of the CSE. The transaction is expected to close on June 30, 2023.Reported Earnings • May 01Full year 2022 earnings released: CA$0.009 loss per share (vs CA$0.006 loss in FY 2021)Full year 2022 results: CA$0.009 loss per share (further deteriorated from CA$0.006 loss in FY 2021). Net loss: CA$4.62m (loss widened 93% from FY 2021).Reported Earnings • Dec 02Third quarter 2022 earnings released: CA$0.001 loss per share (vs CA$0.002 loss in 3Q 2021)Third quarter 2022 results: CA$0.001 loss per share (improved from CA$0.002 loss in 3Q 2021). Net loss: CA$778.0k (loss narrowed 7.3% from 3Q 2021).収支内訳Herbal Dispatch の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史DB:HA9 収益、費用、利益 ( )CAD Millions日付収益収益G+A経費研究開発費31 Dec 2512-24030 Sep 2510-33030 Jun 2510-33031 Mar 2511-23031 Dec 2410-33030 Sep 2410-23030 Jun 248-23031 Mar 246-23031 Dec 235-23030 Sep 233-43030 Jun 232-43031 Mar 231-53031 Dec 220-52030 Sep 220-23030 Jun 220-22031 Mar 221-23031 Dec 211-23030 Sep 211-53030 Jun 210-42031 Mar 210-52031 Dec 200-63030 Sep 200-195030 Jun 200-217031 Mar 200-237031 Dec 191-229030 Sep 19-2-1610131 Dec 183-3017131 May 1810-1411028 Feb 1811-108031 May 175-33031 May 161-210質の高い収益: HA9は現在利益が出ていません。利益率の向上: HA9は現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: HA9は利益を出していないが、過去 5 年間で年間15.3%の割合で損失を削減してきた。成長の加速: HA9の過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: HA9は利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( 16.1% ) と比較することは困難です。株主資本利益率高いROE: HA9は現在利益が出ていないため、自己資本利益率 ( -60.66% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 20:48終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Herbal Dispatch Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • Aug 23Second quarter 2024 earnings released: EPS: CA$0.001 (vs CA$0.006 loss in 2Q 2023)Second quarter 2024 results: EPS: CA$0.001 (up from CA$0.006 loss in 2Q 2023). Revenue: CA$3.65m (up 215% from 2Q 2023). Net income: CA$58.6k (up CA$460.2k from 2Q 2023). Profit margin: 1.6% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue.
Reported Earnings • May 02Full year 2023 earnings released: CA$0.029 loss per share (vs CA$0.092 loss in FY 2022)Full year 2023 results: CA$0.029 loss per share (improved from CA$0.092 loss in FY 2022). Revenue: CA$4.74m (up CA$4.43m from FY 2022). Net loss: CA$2.07m (loss narrowed 55% from FY 2022).
Reported Earnings • Nov 25Third quarter 2023 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 3Q 2022)Third quarter 2023 results: CA$0.001 loss per share (in line with 3Q 2022). Revenue: CA$1.17m (up CA$1.07m from 3Q 2022). Net loss: CA$533.0k (loss narrowed 32% from 3Q 2022).
Reported Earnings • Aug 31Second quarter 2023 earnings released: CA$0.001 loss per share (vs CA$0.003 loss in 2Q 2022)Second quarter 2023 results: CA$0.001 loss per share (improved from CA$0.003 loss in 2Q 2022). Revenue: CA$1.16m (up CA$1.15m from 2Q 2022). Net loss: CA$401.7k (loss narrowed 71% from 2Q 2022).
Reported Earnings • Jun 02First quarter 2023 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 1Q 2022)First quarter 2023 results: CA$0.001 loss per share (in line with 1Q 2022). Net loss: CA$685.8k (loss widened 23% from 1Q 2022).
Reported Earnings • May 01Full year 2022 earnings released: CA$0.009 loss per share (vs CA$0.006 loss in FY 2021)Full year 2022 results: CA$0.009 loss per share (further deteriorated from CA$0.006 loss in FY 2021). Net loss: CA$4.62m (loss widened 93% from FY 2021).
Board Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Drew Malcolm was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Oct 21Herbal Dispatch Inc. announced that it has received CAD 2.078211 million in fundingOn October 20, 2025, Herbal Dispatch Inc. closed the transaction. The company issued 41,564,220 units at a price of CAD 0.05 per Unit for gross proceeds of up to CAD 2,078,211. In connection with the closing of the private placement, the company incurred finder's fees to qualified arm’s length finders (the “finders”) as follows: (a) an aggregate cash payment of CAD 103,495; and (b) the issuance of 599,900 Warrants. Such finder’s fees were paid only to Finders who executed finder’s fee agreements with the Company and who successfully introduced investors that participated in the Private Placement. The transaction included participation from new investors Roderick W. Law Corporation, EPC Holdings Ltd., and ADH Holdings Ltd., for an aggregate of 6,814,420 Units, representing approximately 16.39% of the total Units permitted to be subscribed for under the Private Placement.
お知らせ • Jul 30Herbal Dispatch Inc. announced that it expects to receive CAD 1 million in fundingHerbal Dispatch Inc. announced a non-brokered private placement of up to 20,000,000 units at a price of CAD 0.05 per Unit for gross proceeds of up to CAD 1,000,000. Each Unit shall consist of one common share and one-half common share purchase warrant with each Warrant transferable and exercisable for one common share at a price of CAD 0.08 per share for a period of 24 months after the closing date. The Private Placement shall be completed on a best-efforts basis from eligible purchasers that shall be restricted to accredited investors or other investors meeting exemption requirements for a non-brokered private placement. The closing of the Private Placement is expected to occur before August 29, 2025, and is subject to receipt of all necessary regulatory approvals, including the approval of the CSE. Should the Private Placement be oversubscribed, the Company reserves the right to accept additional funds, subject to the approval of the Canadian Securities Exchange (“CSE”). All securities issued pursuant to the Private Placement will be subject to a four month hold period in accordance with applicable Canadian securities laws.
お知らせ • Apr 08Herbal Dispatch Inc., Annual General Meeting, Jun 10, 2025Herbal Dispatch Inc., Annual General Meeting, Jun 10, 2025.
お知らせ • Mar 25Herbal Dispatch Inc. announced that it has received CAD 0.6 million in fundingHerbal Dispatch Inc. announced that it will receive CAD 600,000 in a round of funding on March 25, 2025. The company will also issue 3,000,000 warrants in the transaction. Each warrants are convertible to common stock of the company at an exercise price of $0.065 per share. The warrants will expire on March 19, 2029. The company has received debt in the transaction which incurs interest rate of 18% p.a. and is repayable in equal monthly instalments of $29,955. The warrants carry a hold period of four months. The company has incurred a closing fee of $12,000 in the transaction. The transaction included participation from Philip Campbell representing one of the Lenders, and via a wholly owned company, and provided $100,000 of the debt and will receive 500,100 of the warrants issued.
お知らせ • Oct 09Herbal Dispatch Inc., Annual General Meeting, Dec 16, 2024Herbal Dispatch Inc., Annual General Meeting, Dec 16, 2024.
Reported Earnings • Aug 23Second quarter 2024 earnings released: EPS: CA$0.001 (vs CA$0.006 loss in 2Q 2023)Second quarter 2024 results: EPS: CA$0.001 (up from CA$0.006 loss in 2Q 2023). Revenue: CA$3.65m (up 215% from 2Q 2023). Net income: CA$58.6k (up CA$460.2k from 2Q 2023). Profit margin: 1.6% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue.
New Risk • May 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$472k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$472k free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Market cap is less than US$10m (€2.76m market cap, or US$2.98m). Minor Risks Shareholders have been diluted in the past year (11% increase in shares outstanding). Revenue is less than US$5m (CA$5.7m revenue, or US$4.2m).
Board Change • May 13Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Drew Malcolm was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • May 10Herbal Dispatch Inc. Announces Board ChangesHerbal Dispatch Inc. announces that effective May 8, 2024, Jeremy South has resigned as a Director and Chairman of the Company. The Company is grateful to Mr. South for his contribution throughout the yearsand wishes him all the best in his future endeavors. The Honourable Herb Dhaliwal, a Director the Company, has agreed to be appointed as interim Chairman of the Company until a permanent successoris appointed.
Reported Earnings • May 02Full year 2023 earnings released: CA$0.029 loss per share (vs CA$0.092 loss in FY 2022)Full year 2023 results: CA$0.029 loss per share (improved from CA$0.092 loss in FY 2022). Revenue: CA$4.74m (up CA$4.43m from FY 2022). Net loss: CA$2.07m (loss narrowed 55% from FY 2022).
お知らせ • Mar 21Herbal Dispatch Inc. announced that it expects to receive CAD 1 million in fundingHerbal Dispatch Inc. announced on best-effort basis a non-brokered private placement of up to 20,000,000 units at a price of CAD 0.05 per unit for the gross proceeds of CAD 1,000,000 on March 20, 2024. Each Unit shall consist of one common share and one common share warrant with each Warrant exercisable for one common share at a price of CAD 0.06 per share for a period of 24 months after the closing date. Should the Private Placement be oversubscribed, the Company reserves the right to accept additional funds, subject to the approval of the Canadian Securities Exchange and is also subjected to regulatory approvals. The closing of the Private Placement is expected to occur before April 5, 2024. All securities issued pursuant to the private placement will be subject to a four month hold period in accordance with applicable Canadian securities laws.
お知らせ • Dec 16Herbal Dispatch Inc. announced that it expects to receive CAD 0.938 million in fundingHerbal Dispatch Inc. announced that it has issued an unsecured convertible debenture in the principal amount of CAD 938,000 for gross proceeds of CAD 938,000 on December 15, 2023. The transaction included participation from directors. The company also amended the terms of a convertible debenture in the principal amount of CAD 438,000 owing to another director of the company. The debenture bears interest at an annual rate of 14% per annum, payable monthly, and matures on January 31, 2025. The transaction is subject to the approval of the Canadian Securities Exchange. The debenture will also be convertible, at the holder’s option into common shares of the company at a price of CAD 0.05 per share, and at the it’s election, during any period where the trading price of the it’s common shares is CAD 0.10 or greater for a period of 20 consecutive trading days. The company issued principal amount of CAD 500,000 to a director of the company in its first tranche.
Reported Earnings • Nov 25Third quarter 2023 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 3Q 2022)Third quarter 2023 results: CA$0.001 loss per share (in line with 3Q 2022). Revenue: CA$1.17m (up CA$1.07m from 3Q 2022). Net loss: CA$533.0k (loss narrowed 32% from 3Q 2022).
お知らせ • Oct 07Herbal Dispatch Inc., Annual General Meeting, Dec 15, 2023Herbal Dispatch Inc., Annual General Meeting, Dec 15, 2023.
Reported Earnings • Aug 31Second quarter 2023 earnings released: CA$0.001 loss per share (vs CA$0.003 loss in 2Q 2022)Second quarter 2023 results: CA$0.001 loss per share (improved from CA$0.003 loss in 2Q 2022). Revenue: CA$1.16m (up CA$1.15m from 2Q 2022). Net loss: CA$401.7k (loss narrowed 71% from 2Q 2022).
Reported Earnings • Jun 02First quarter 2023 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 1Q 2022)First quarter 2023 results: CA$0.001 loss per share (in line with 1Q 2022). Net loss: CA$685.8k (loss widened 23% from 1Q 2022).
お知らせ • May 27Herbal Dispatch Inc. announced that it expects to receive CAD 1 million in fundingHerbal Dispatch Inc. announced a non-brokered private placement of up to 100,000,000 units at a price of CAD 0.01 per unit for the gross proceeds of CAD 1,000,000 on May 25, 2023. Each unit consist of one common share and one common share warrant. Each warrant is exercisable for one common share at a price of CAD 0.05 per share for a period of 24 months after the closing date. All securities issued pursuant to the private placement will be subject to a four month hold period. The transaction is subject to the approval of all necessary regulatory approvals including the approval of the CSE. The transaction is expected to close on June 30, 2023.
Reported Earnings • May 01Full year 2022 earnings released: CA$0.009 loss per share (vs CA$0.006 loss in FY 2021)Full year 2022 results: CA$0.009 loss per share (further deteriorated from CA$0.006 loss in FY 2021). Net loss: CA$4.62m (loss widened 93% from FY 2021).
Reported Earnings • Dec 02Third quarter 2022 earnings released: CA$0.001 loss per share (vs CA$0.002 loss in 3Q 2021)Third quarter 2022 results: CA$0.001 loss per share (improved from CA$0.002 loss in 3Q 2021). Net loss: CA$778.0k (loss narrowed 7.3% from 3Q 2021).